Search

Your search keyword '"Funck-Brentano C"' showing total 24 results
Start Over Author "Funck-Brentano C" Topic heart failure
24 results on '"Funck-Brentano C"'

1. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.

Author

Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, and Salem JE

Subjects
Adverse Drug Reaction Reporting Systems, Aged, Aged, 80 and over, Benzamides, Cardiotoxicity, Databases, Factual, Heart Failure diagnosis, Heart Failure epidemiology, Humans, Male, Middle Aged, Nitriles, Phenylthiohydantoin adverse effects, Prostatic Neoplasms diagnosis, Prostatic Neoplasms epidemiology, Retrospective Studies, Risk Assessment, Risk Factors, Tachycardia, Supraventricular diagnosis, Tachycardia, Supraventricular epidemiology, Time Factors, Androgen Antagonists adverse effects, Androstenes adverse effects, Antineoplastic Agents, Hormonal adverse effects, Heart Failure chemically induced, Pharmacovigilance, Phenylthiohydantoin analogs & derivatives, Prostatic Neoplasms drug therapy, Tachycardia, Supraventricular chemically induced
Abstract

Background: Abiraterone and enzalutamide are recently-approved androgen deprivation therapies (ADTs) for metastatic prostate cancer, with unknown cardiac safety profiles. Abiraterone has a propensity to hypermineralocorticism on top of androgen deprivation, so might carry an additional risk for atrial tachyarrhythmia (AT) and heart failure (HF) compared with other ADTs., Aim: To determine if abiraterone was associated with an increased proportion of AT and HF reports among all suspected adverse drug reactions (ADRs) reported in several pharmacovigilance databases compared with enzalutamide, other ADTs and all other drugs., Methods: In this observational retrospective pharmacovigilance study, we performed a disproportionality analysis of reports of suspected ADRs in men in the French pharmacovigilance database, the European pharmacovigilance database and the international pharmacovigilance database VigiBase, to evaluate the reporting odds ratios (RORs) of AT and HF for abiraterone compared with enzalutamide, other ADTs and all other drugs., Results: In the 5,759,781 ADR reports in men in VigiBase, 55,070 pertained to ADTs. The RORs for AT for abiraterone versus enzalutamide, other ADTs and all other drugs were 4.1 (95% confidence interval 3.1-5.3), 3.7 (3-4.5) and 3.2 (2.7-3.7), respectively (P<0.0001 for all). The corresponding RORs for HF were 2.5 (2-3), 1.5 (1.3-1.7) and 2 (1.7-2.3), respectively (P<0.0001 for all). These results were concordant with the French and European pharmacovigilance databases. Mean times to AT and HF onset were shorter with abiraterone (5.2±0.8 and 4.5±0.6 months, respectively) versus other ADTs (13.3±3.2 and 9.2±1.1 months, respectively) (both P<0.05). Cases on abiraterone versus other ADTs were more frequently associated with at least two ADR terms, including AT, HF, hypokalaemia, hypertension and oedema (13.6% vs 6%; P<0.0001). For abiraterone, age, but not dose, was associated with reporting of AT and HF versus any other ADR., Conclusions: Compared with other ADTs, abiraterone was associated with higher reporting of AT and HF, associated with hypokalaemia, hypertension and oedema. These findings are consistent with the hypermineralocorticism induced by abiraterone, but not by other ADTs., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)

Published
2020
Full Text
View/download PDF

2. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Author

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, and Ponikowski P

Subjects
Algorithms, Antihypertensive Agents therapeutic use, Cardiotonic Agents therapeutic use, Europe, Heart Failure diagnosis, Humans, Natriuretic Peptides, Renin-Angiotensin System, Societies, Medical, Stroke Volume, Ventricular Function, Left, Heart Failure drug therapy
Published
2012
Full Text
View/download PDF

3. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.

Author

Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, Follath F, Goulder M, and Willenheimer R

Subjects
Adrenergic beta-Antagonists adverse effects, Aged, Analysis of Variance, Angiotensin Receptor Antagonists adverse effects, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors adverse effects, Antihypertensive Agents adverse effects, Bisoprolol adverse effects, Enalapril adverse effects, Female, Glomerular Filtration Rate, Humans, Male, Multivariate Analysis, Statistics as Topic, Treatment Outcome, Adrenergic beta-Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Bisoprolol therapeutic use, Enalapril therapeutic use, Heart Failure drug therapy
Abstract

Aims: Angiotensin-converting enzyme inhibitors (ACE-Is) and beta-blockers are associated with improved outcome in patients with chronic heart failure (CHF). In this post hoc analysis of the CIBIS III trial, we examined the influence of the order of drug administration on clinical events and achieved dose. We also assessed the relations between dose levels and baseline variables or adverse events., Methods and Results: In the CIBIS III trial, 1010 patients (mean age: 72.4 years; mean ejection fraction: 28.8%; male: 68.2%) with stable CHF were randomized to up-titration of monotherapy with either bisoprolol (target dose 10 mg o.d.) or enalapril (target dose 10 mg b.i.d.) for 6 months, followed by their combination for 6-24 months. Endpoints were mortality or all-cause hospitalization, mortality alone and mortality or cardiovascular hospitalization. The study drug (ACE-I or beta-blocker) was last prescribed at ≥50% of target dose to significantly more patients for the first initiated drug in both treatment groups (both P< 0.001). Sixty per cent of endpoints were reached during the monotherapy phase and randomized treatment during monotherapy was not a predictor of the three assessed outcomes. Monotherapy phase was the strongest independent predictor of outcome (P< 0.0001 for all endpoints). Older age, NYHA class III, impaired renal function, lower body weight and blood pressure at baseline, and hypotension, bradycardia and heart failure during treatment were associated with the inability to reach high dose of both study drugs., Conclusion: The order of drug administration plays an important role in whether CHF patients reach target doses of bisoprolol and enalapril. For both study drugs, the dose level reached was associated with baseline characteristics and adverse events. In CHF patients not treated with an ACE-I or a beta-blocker, the duration of monotherapy with either type of drug should be shorter than 6 months.

Published
2011
Full Text
View/download PDF

4. Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.

Author

Krum H, van Veldhuisen DJ, Funck-Brentano C, Vanoli E, Silke B, Erdmann E, Follath F, Ponikowski P, Goulder M, Meyer W, Lechat P, and Willenheimer R

Subjects
Aged, Chronic Disease, Drug Therapy, Combination, Female, Heart Failure mortality, Hospitalization, Humans, Male, Adrenergic beta-Antagonists administration & dosage, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Bisoprolol administration & dosage, Death, Sudden, Cardiac prevention & control, Enalapril administration & dosage, Heart Failure drug therapy
Abstract

Background: Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting., Methods: We randomized 1010 patients with mild or moderate, stable CHF and left ventricular ejection fraction ≤35%, without ACEI, β-blocker or angiotensin-receptor-blocker therapy, to either bisoprolol (n = 505) or enalapril (n = 505) for 6 months, followed by their combination for 6-24 months. The two strategies were blindly compared regarding adjudicated mode of death, including sudden death and progressive pump failure death., Results: During the monotherapy phase, 8 of 23 deaths in the bisoprolol-first group were sudden, compared to 16 of 32 in the enalapril-first group: hazard ratio (HR) for sudden death 0.50; 95% confidence interval (CI) 0.21-1.16; P= 0.107. At 1 year, 16 of 42 versus 29 of 60 deaths were sudden: HR 0.54; 95% CI 0.29-1.00; P= 0.049. At study end, 29 of 65 versus 34 of 73 deaths were sudden: HR 0.84; 95% CI 0.51-1.38; P= 0.487. Comparable figures for pump failure death were: monotherapy, 7 of 23 deaths versus 2 of 32: HR 3.43; 95% CI 0.71-16.53; P= 0.124, at 1 year, 13 of 42 versus 5 of 60: HR 2.57; 95% CI 0.92-7.20; P= 0.073, at study end, 17 of 65 versus 7 of 73: HR 2.39; 95% CI 0.99-5.75; P= 0.053. There were no significant between-group differences in any other fatal events., Conclusion: Initiating therapy with bisoprolol compared to enalapril decreased the risk of sudden death during the first year in this mild systolic CHF cohort. This was somewhat offset by an increase in pump failure deaths in the bisoprolol-first cohort., (© 2010 Blackwell Publishing Ltd.)

Published
2011
Full Text
View/download PDF

5. Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others".

Author

Willenheimer R, Krum H, van Veldhuisen DJ, Funck-Brentano C, Erdmann E, and Meyer WR

Subjects
Adrenergic beta-Antagonists administration & dosage, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Bisoprolol administration & dosage, Enalapril administration & dosage, Heart Failure mortality, Hospitalization, Humans, Randomized Controlled Trials as Topic, Research Design standards, Treatment Outcome, Heart Failure drug therapy
Published
2006
Full Text
View/download PDF

6. Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II).

Author

Simon T, Mary-Krause M, Funck-Brentano C, Lechat P, and Jaillon P

Subjects
Death, Sudden, Cardiac, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Survival Analysis, Treatment Outcome, Treatment Refusal, Adrenergic beta-Antagonists administration & dosage, Bisoprolol administration & dosage, Heart Failure drug therapy
Abstract

Aims: Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain., Methods and Results: We classified by tertile the 2647 patients enrolled in CIBIS II according to the last tolerated dose: low dose (LD: 1.25, 2.5 or 3.75mg/day, n=434), moderate dose (MD: 5 or 7.5mg/day, n=328) and high dose (HD: 10mg/day, n=565) of bisoprolol or placebo (LD=234, MD=278 and HD=808). In both groups, patients tolerating only low doses were significantly older with more severe New York Heart Association (NYHA) functional class and higher frequency of co-morbidities. Treatment withdrawal was associated with a significant increase of mortality in the bisoprolol group (relative hazard (RH)=2.13, 95% confidence interval (CI)=1.43-3.17, p=0.0002). After adjustment, all-cause mortality was significantly reduced in the bisoprolol group compared to placebo regardless of the dose level considered: LD (RH=0.66, 95% CI=0.48-0.92), MD (RH=0.33, 95% CI=0.21-0.51) or HD (RH=0.59, 95% CI=0.40-0.89)., Conclusions: Bisoprolol reduces mortality in CHF patients at all tolerated dose levels and its withdrawal increases the risk of mortality. Efforts should be made to maintain bisoprolol therapy based on the individual patient's tolerability.

Published
2003
Full Text
View/download PDF

7. Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2).

Author

Funck-Brentano C, Lancar R, Hansen S, Hohnloser SH, and Vanoli E

Subjects
Aged, Drug Administration Schedule, Female, Follow-Up Studies, Heart Failure mortality, Humans, Male, Middle Aged, Multivariate Analysis, Patient Compliance, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Risk Assessment, Survival Rate, Treatment Outcome, Adrenergic beta-Antagonists administration & dosage, Bisoprolol administration & dosage, Heart Failure drug therapy, Hospitalization statistics & numerical data
Abstract

Aims: Predictive factors for medical events and interactions between events were not reported in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). We examined the interactions among death, permanent treatment withdrawals, nonlethal cardiovascular hospitalizations and their own occurrence in a given patient, the treatment received, and baseline variables during CIBIS-2., Methods and Results: A Cox model for censored data was used to analyze the relations among baseline variables, medical events, and their interactions with treatment. We used competitive risk analysis to examine the interactions between successive events in a given patient during follow-up. No baseline variable predicted the reduction of mortality with bisoprolol. Withdrawal from bisoprolol therapy was more frequent in patients whose baseline heart rate was in the lower tertile of the distribution (P =.0002) but otherwise was not different between patients randomized to bisoprolol and to placebo. Event history analysis revealed that bisoprolol reduced mortality (P =.0006) and hospitalizations for nonlethal cardiovascular events (P =.003) in patients in whom treatment was not permanently withdrawn. Analysis of survival curves in patients who permanently discontinued treatment showed that bisoprolol did not reduce mortality compared with placebo in this population (relative risk 1.03, 95% CI 0.67-1.59; P =.88). Recurrent nonlethal events were reduced by bisoprolol., Conclusion: In CIBIS-2, medical events were significantly influenced by treatment withdrawal. Patients who derive benefit from bisoprolol therapy are those in whom treatment is not permanently withdrawn.

Published
2001
Full Text
View/download PDF

8. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II).

Author

Simon T, Mary-Krause M, Funck-Brentano C, and Jaillon P

Subjects
Aged, Female, Heart Failure mortality, Heart Failure physiopathology, Humans, Male, Middle Aged, Multivariate Analysis, Prognosis, Sex Factors, Survival Analysis, Adrenergic beta-Antagonists therapeutic use, Antihypertensive Agents therapeutic use, Bisoprolol therapeutic use, Heart Failure drug therapy
Abstract

Background: Whether female sex is associated with a better prognosis in patients with congestive heart failure (CHF) remains uncertain. The Cardiac Insufficiency Bisoprolol Study (CIBIS) II showed that bisoprolol reduced all-cause mortality and morbidity rates in CHF patients treated with diuretics and ACE inhibitors. We examined whether survival was different in men (n=2132) and women (n=515) enrolled in CIBIS II., Methods and Results: Women differed from men with regard to age, NYHA functional classification, primary cause of CHF, and risk factors such as left bundle-branch block. After adjustment for baseline differences, the probability of all-cause mortality was significantly reduced by 36% in women compared with that in men (hazard ratio 0.64, 95% CI 0.47 to 0.86, P:=0.003). Women also had a 39% reduction in cardiovascular deaths (hazard ratio 0.64, 95% CI 0.45 to 0.91, P:=0.01) and a 70% reduction in deaths from pump failure (hazard ratio 0.30, 95% CI 0.13 to 0.70, P:=0.005) compared with men. Kaplan-Meier survival analysis revealed a significant reduction in all-cause mortality among women treated with bisoprolol compared with men (6% versus 12% P:=0.01) but not among women treated with placebo (13% versus 18%, P:=0.10). However, this sex/ss-blocker effect was not significant in multivariate analysis., Conclusions: These results indicate that regardless of ss-blocker treatment and baseline clinical profile, female sex is a significant independent predictor of survival in patients with CHF.

Published
2001
Full Text
View/download PDF

9. Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks.

Author

Funck-Brentano C, Lancar R, Le Heuzey JY, Lardoux H, Soubrié C, and Lechat P

Subjects
Aged, Female, Heart Failure physiopathology, Humans, Male, Middle Aged, Prognosis, Randomized Controlled Trials as Topic, Risk Assessment, Survival Analysis, Adrenergic beta-Antagonists therapeutic use, Bisoprolol therapeutic use, Heart Failure drug therapy, Heart Failure mortality
Abstract

Background: The risk of occurrence of medical events in a clinical trial is competitive in nature; that is, in a given patient the risk of having a critical event depends on the amount of time elapsed since random assignment and on the previous events that may have occurred in the patient. The purpose of this study was to examine the relations between baseline variables, the interactions between treatment, bisoprolol, or placebo, and the occurrence of critical events during the CIBIS trial, a mortality and morbidity trial of beta-blockade in patients with heart failure., Methods and Results: A Cox model for censored data was used to analyze the relations between baseline variables, total deaths, permanent treatment withdrawals, nonlethal cardiovascular events, and their interactions with bisoprolol or placebo. We examined the influence of treatment on the occurrence of deaths, permanent treatment withdrawals, and nonlethal cardiovascular events by using the technique of event history analysis, which takes into account competitive risks between events. Compared with placebo, bisoprolol reduced mortality rates in patients with a left ventricular ejection fraction < or =20% (relative risk [RR] 0.49; 95% confidence interval [CI] 0.27 to 0.88; P =.02). In patients whose baseline heart rate was in the upper tertile of distribution, permanent treatment withdrawals were less frequent in patients randomly assigned to bisoprolol than in patients randomly assigned to placebo (RR 0.50; 95% CI 0.28 to 0.88; P =.02). Bisoprolol reduced the incidence of nonlethal cardiac events in patients in whom heart failure was present for at least 4 years (RR 0.44; 95% CI 0.27 to 0.71; P <.01). Event history analysis revealed that among patients who died under treatment after having at least 1 nonlethal cardiovascular event, 20 patients were treated with placebo but only 7 patients were treated with bisoprolol (RR 0.41; 95% CI 0.17 to 0.98; P <.05)., Conclusions: Some patients with heart failure derive more benefit from beta-blocker therapy than others. In the CIBIS trial, they are those patients with the lower left ventricular ejection fractions and those who have nonlethal cardiovascular events but in whom beta-blocker therapy is not permanently discontinued.

Published
2000
Full Text
View/download PDF

10. Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure.

Author

Funck-Brentano C, Chatellier G, and Alexandre JM

Subjects
Aged, Drug Therapy, Combination, Heart Failure blood, Humans, Male, Sodium blood, Acute Kidney Injury chemically induced, Enalapril adverse effects, Furosemide adverse effects, Heart Failure drug therapy
Abstract

A patient with congestive heart failure and moderate renal insufficiency developed severe reversible non-oliguric renal failure while on frusemide and enalapril. Renal failure developed when enalapril was given in the presence of pronounced sodium depletion. When positive sodium balance was restored the plasma creatinine concentration began to fall while angiotensin converting enzyme inhibition remained effective and blood pressure was stable. These observations suggest that the degree of sodium depletion plays an important role in the tendency for angiotensin converting enzyme inhibitors to induce renal failure in patients with congestive heart failure and moderate renal insufficiency. Restoration of a positive sodium balance promotes the recovery of renal function after the combined administration of angiotensin converting enzyme inhibitors and diuretics.

Published
1986
Full Text
View/download PDF

11. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Author

Knuuti, Juhani, Wijns, William, Saraste, Antti, Capodanno, Davide, Barbato, Emanuele, Funck-Brentano, Christian, Prescott, Eva, Storey, Robert F, Deaton, Christi, Cuisset, Thomas, Agewall, Stefan, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Gersh, Bernard J, Svitil, Pavel, Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Valgimigli, Marco, Achenbach, Stephan, Bax, Jeroen J, Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Leclercq C, Lewis BS, Merkely B, Mueller C, Petersen S, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B, Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie [Hôpital de la Timone - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Knuuti, Juhani, Wijns, William, Saraste, Antti, Capodanno, Davide, Barbato, Emanuele, Funck-Brentano, Christian, Prescott, Eva, Storey, Robert F, Deaton, Christi, Cuisset, Thoma, Agewall, Stefan, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Gersh, Bernard J, Svitil, Pavel, Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Valgimigli, Marco, Achenbach, Stephan, Bax, Jeroen J, Neumann FJ, Sechtem U, Banning AP, Bonaros N, Bueno H, Bugiardini R, Chieffo A, Crea F, Czerny M, Delgado V, Dendale P, Flachskampf FA, Gohlke H, Grove EL, James S, Katritsis D, Landmesser U, Lettino M, Matter CM, Nathoe H, Niessner A, Patrono C, Petronio AS, Pettersen SE, Piccolo R, Piepoli MF, Popescu BA, Räber L, Richter DJ, Roffi M, Roithinger FX, Shlyakhto E, Sibbing D, Silber S, Simpson IA, Sousa-Uva M, Vardas P, Witkowski A, Zamorano JL, Achenbach S, Agewall S, Barbato E, Bax JJ, Capodanno D, Cuisset T, Deaton C, Dickstein K, Edvardsen T, Escaned J, Funck-Brentano C, Gersh BJ, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Prescott E, Saraste A, Storey RF, Svitil P, Valgimigli M, Windecker S, Aboyans V, Baigent C, Collet JP, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Benkhedda S, Metzler B, Sujayeva V, Cosyns B, Kusljugic Z, Velchev V, Panayi G, Kala P, Haahr-Pedersen SA, Kabil H, Ainla T, Kaukonen T, Cayla G, Pagava Z, Woehrle J, Kanakakis J, Tóth K, Gudnason T, Peace A, Aronson D, Riccio C, Elezi S, Mirrakhimov E, Hansone S, Sarkis A, Babarskiene R, Beissel J, Maempel AJC, Revenco V, de Grooth GJ, Pejkov H, Juliebø V, Lipiec P, Santos J, Chioncel O, Duplyakov D, Bertelli L, Dikic AD, Studenčan M, Bunc M, Alfonso F, Bäck M, Zellweger M, Addad F, Yildirir A, Sirenko Y, Clapp B, Clinical sciences, Cardio-vascular diseases, Cardiology, Knuuti, Juhani [0000-0003-3156-9593], Apollo - University of Cambridge Repository, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), University of Zurich, Knuuti, J., Wijns, W., Achenbach, S., Agewall, S., Barbato, E., Bax, J. J., Capodanno, D., Cuisset, T., Deaton, C., Dickstein, K., Edvardsen, T., Escaned, J., Funck-Brentano, C., Gersh, B. J., Gilard, M., Hasdai, D., Hatala, R., Mahfoud, F., Masip, J., Muneretto, C., Prescott, E., Saraste, A., Storey, R. F., Svitil, P., Valgimigli, M., Windecker, S., Aboyans, V., Baigent, C., Collet, J. -P., Dean, V., Delgado, V., Fitzsimons, D., Gale, C. P., Grobbee, D. E., Halvorsen, S., Hindricks, G., Iung, B., Juni, P., Katus, H. A., Landmesser, U., Leclercq, C., Lettino, M., Lewis, B. S., Merkely, B., Mueller, C., Petersen, S., Petronio, A. S., Richter, D. J., Roffi, M., Shlyakhto, E., Simpson, I. A., Sousa-Uva, M., Touyz, R. M., Benkhedda, S., Metzler, B., Sujayeva, V., Cosyns, B., Kusljugic, Z., Velchev, V., Panayi, G., Kala, P., Haahr-Pedersen, S. A., Kabil, H., Ainla, T., Kaukonen, T., Cayla, G., Pagava, Z., Woehrle, J., Kanakakis, J., Toth, K., Gudnason, T., Peace, A., Aronson, D., Riccio, C., Elezi, S., Mirrakhimov, E., Hansone, S., Sarkis, A., Babarskiene, R., Beissel, J., Cassar Maempel, A. J., Revenco, V., de Grooth, G. J., Pejkov, H., Juliebo, V., Lipiec, P., Santos, J., Chioncel, O., Duplyakov, D., Bertelli, L., Dikic, A. D., Studencan, M., Bunc, M., Alfonso, F., Back, M., Zellweger, M., Addad, F., Yildirir, A., Sirenko, Y., and Clapp, B.

Subjects
anti-ischaemic drug, chronic coronary syndromes, medicine.medical_treatment, [SDV]Life Sciences [q-bio], lipid-lowering drugs, Diagnostic Techniques, Cardiovascular, antithrombotic therapy, Disease, 030204 cardiovascular system & hematology, Guideline, Coronary artery disease, 0302 clinical medicine, Disease management (health), Societies, Medical, ComputingMilieux_MISCELLANEOUS, chronic coronary syndrome, angina pectori, Disease Management, food and beverages, imaging, risk assessment, Syndrome, 3. Good health, Natural history, Europe, Cardiology, Cardiology and Cardiovascular Medicine, coronary artery disease, medicine.medical_specialty, lifestyle modifications, anti-ischaemic drugs, Ischemia, 610 Medicine & health, vasospastic angina, Guidelines, Revascularization, diagnostic testing, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, angina pectoris, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, medicine, Journal Article, Humans, business.industry, screening, fungi, 030229 sport sciences, medicine.disease, lipid-lowering drug, Angina pectoris, Anti-ischaemic drugs, Antithrombotic therapy, Chronic coronary syndromes, Diagnostic testing, Imaging, Lifestyle modifications, Lipid-lowering drugs, Microvascular angina, Myocardial ischaemia, Myocardial revascularization, Risk assessment, Screening, Vasospastic angina, myocardial ischaemia, myocardial revascularization, Heart failure, microvascular angina, Chronic Disease, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, lifestyle modification, Coronary Artery Disease/diagnosis, business, Fibrinolytic agent
Abstract

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

Published
2019

12. Third universal definition of myocardial infarction

Author

Thygesen, K, Alpert, Js, Jaffe, As, Simoons, Ml, Chaitman, Br, White, Hd, the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Authors/Task Force Members Chairpersons, Biomarker, Subcommittee, Katus, Ha, Apple, Fs, Lindahl, B, Morrow, Da, Ecg, Subcommittee, Clemmensen, Pm, Johanson, P, Hod, H, Imaging, Subcommittee, Underwood, R, Bax, Jj, Bonow, Ro, Pinto, F, Gibbons, Rj, Classification, Subcommittee, Fox, Ka, Atar, D, Newby, Lk, Galvani, M, Hamm, Cw, Intervention, Subcommittee, Uretsky, Bf, Gabriel Steg, P, Wijns, W, Bassand, Jp, Menasché, P, Ravkilde, J, Trials, Registries, Subcommittee, Ohman, Em, Antman, Em, Wallentin, Lc, Armstrong, Pw, Heart Failure Subcommittee, Januzzi, Jl, Nieminen, Ms, Gheorghiade, M, Filippatos, G, Epidemiology, Subcommittee, Luepker, Rv, Fortmann, Sp, Rosamond, Wd, Levy, D, Wood, D, Global Perspective Subcommittee, Smith, Sc, Hu, D, Lopez Sendon JL, Robertson, Rm, Weaver, D, Tendera, M, Bove, Aa, Parkhomenko, An, Vasilieva, Ej, Mendis, S, ESC Committee for Practice Guidelines, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewers, Morais, J, Aguiar, C, Almahmeed, W, Arnar, Do, Barili, F, Bloch, Kd, Bolger, Af, Bøtker, He, Bozkurt, B, Bugiardini, R, Cannon, C, de Lemos, J, Eberli, Fr, Escobar, E, Hlatky, M, James, S, Kern, Kb, Moliterno, Dj, Mueller, C, Neskovic, An, Pieske, Bm, Schulman, Sp, Storey, Rf, Taubert, Ka, Vranckx, P, Wagner, D. R., Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow JJ, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Botker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C, Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR., Cardiology, lLindahl B, K. Thygesen, J. S. Alpert, A. S. Jaffe, M. L. Simoon, B. R. Chaitman, H. D. White, H. A. Katu, F. S. Apple, B. Lindahl, D. A. Morrow, P. M. Clemmensen, P. Johanson, H. Hod, R. Underwood, J. J. Bax, R. O. Bonow, F. Pinto, R. J. Gibbon, K. A. Fox, D. Atar, L. K. Newby, M. Galvani, C. W. Hamm, B. F. Uretsky, P. Gabriel Steg, W. Wijn, J.-P. Bassand, P. Menasche, J. Ravkilde, E. M. Ohman, E. M. Antman, L. C. Wallentin, P. W. Armstrong, J. L. Januzzi, M. S. Nieminen, M. Gheorghiade, G. Filippato, R. V. Luepker, S. P. Fortmann, W. D. Rosamond, D. Levy, D. Wood, S. C. Smith, D. Hu, J.-L. Lopez-Sendon, R. M. Robertson, D. Weaver, M. Tendera, A. A. Bove, A. N. Parkhomenko, E. J. Vasilieva, S. Mendi, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoe, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirne, A. Torbicki, A. Vahanian, S. Windecker, J. Morai, C. Aguiar, W. Almahmeed, D. O. Arnar, F. Barili, K. D. Bloch, A. F. Bolger, H. E. Botker, B. Bozkurt, R. Bugiardini, C. Cannon, J. de Lemo, F. R. Eberli, E. Escobar, M. Hlatky, S. Jame, K. B. Kern, D. J. Moliterno, C. Mueller, A. N. Neskovic, B. M. Pieske, S. P. Schulman, R. F. Storey, K. A. Taubert, P. Vranckx, D. R. Wagner, Thygesen, K, Alpert, J, Jaffe, A, Simoons, Ml, Chaitman, Br, White, Hd, Katus, Ha, Apple, F, Lindahl, B, Morrow, Da, Clemmensen, Pm, Johanson, P, Hod, H, Underwood, R, Bax, Jj, Bonow, Jj, Pinto, F, Gibbons, Rj, Fox, Ka, Atar, D, Newby, Lk, Galvani, M, Hamm, Cw, Uretsky, Bf, Steg, Pg, Wijns, W, Bassand, Jp, Menasche, P, Ravkilde, J, Ohman, Em, Antman, Em, Wallentin, Lc, Armstrong, Pw, Januzzi, Jl, Nieminen, M, Gheorghiade, M, Filippatos, G, Luepker, Rv, Fortmann, Sp, Rosamond, Wd, Levy, D, Wood, D, Smith, Sc, Hu, D, Lopez-Sendon, Jl, Robertson, Rm, Weaver, D, Tendera, M, Bove, Aa, Parkhomenko, An, Vasilieva, Ej, Mendis, S, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Funck-Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Torbicki, A, Vahanian, A, Windecker, S, Morais, J, Aguiar, C, Almahmeed, W, Arnar, Do, Barili, F, Bloch, Kd, Bolger, Af, Botker, He, Bozkurt, B, Bugiardini, R, Cannon, C, de Lemos, J, Eberli, Fr, Escobar, E, Hlatky, M, James, S, Kern, Kb, Moliterno, Dj, Mueller, C, Neskovic, An, Pieske, Bm, Schulman, Sp, Storey, Rf, Taubert, Ka, Vranckx, P, and Wagner, Dr

Subjects
High-sensitivity troponin, Ticagrelor, Chest pain unit, Quality Assurance, Health Care, Epidemiology, medicine.medical_treatment, Myocardial Infarction, Myocardial ischaemia, Global Health, Early invasive strategy, Electrocardiography, Stent, Myocardial Revascularization, Myocardial infarction, Coronary Artery Bypass, Intraoperative Complications, Left bundle branch block, Health Policy, Electrocardiography in myocardial infarction, Cangrelor, Stents, Acute coronary syndrome, Cardiology and Cardiovascular Medicine, Prasugrel, Diagnostic Imaging, medicine.medical_specialty, Public Policy, Risk Assessment, Vorapaxar, Percutaneous Coronary Intervention, Physiology (medical), Terminology as Topic, Humans, Enoxaparin, Bypass surgery, Community and Home Care, Heart Failure, Rhythm monitoring, Aspirin, Unstable angina, Angioplasty, Recommendation, ta3121, medicine.disease, Myocardial infarction diagnosis, Bivalirudin, Biomarkers, Time Factors, Platelet inhibition, Consensus Development Conferences as Topic, Diagnostic Techniques, Cardiovascular, Myocardial Ischemia, Guideline, Diabete, Nitrate, Left ventricular hypertrophy, Coronary artery disease, Rivaroxaban, Recurrence, Apixaban, Clinical Trials as Topic, Graft Occlusion, Vascular, Atherothrombosi, Acute cardiac care, Right bundle branch block, Clopidogrel, Dabigatran, Prosthesis Failure, AHA Scientific Statements, Practice Guidelines as Topic, Cardiology, Biological Markers, Radiology, Critical Care, Glycoprotein IIb/IIIa inhibitor, European Society of Cardiology, Diagnosis, Differential, Anticoagulation, Internal medicine, medicine, Beta-blocker, cardiovascular diseases, Heparin, business.industry, Revascularization, Cardiovascular Surgical Procedures, MYOCARDIAL INFARCTION, Statin, Percutaneous coronary intervention, Arrhythmias, Cardiac, Cardiac Imaging Techniques, Fondaparinux, Heart failure, Non-ST-elevation myocardial infarction, business
Abstract

ACCF : American College of Cardiology Foundation ACS : acute coronary syndrome AHA : American Heart Association CAD : coronary artery disease CABG : coronary artery bypass grafting CKMB : creatine kinase MB isoform cTn : cardiac troponin CT : computed tomography CV : coefficient of variation ECG : electrocardiogram ESC : European Society of Cardiology FDG : fluorodeoxyglucose h : hour(s) HF : heart failure LBBB : left bundle branch block LV : left ventricle LVH : left ventricular hypertrophy MI : myocardial infarction mIBG : meta-iodo-benzylguanidine min : minute(s) MONICA : Multinational MONItoring of trends and determinants in CArdiovascular disease) MPS : myocardial perfusion scintigraphy MRI : magnetic resonance imaging mV : millivolt(s) ng/L : nanogram(s) per litre Non-Q MI : non-Q wave myocardial infarction NSTEMI : non-ST-elevation myocardial infarction PCI : percutaneous coronary intervention PET : positron emission tomography pg/mL : pictogram(s) per millilitre Q wave MI : Q wave myocardial infarction RBBB : right bundle branch block sec : second(s) SPECT : single photon emission computed tomography STEMI : ST elevation myocardial infarction ST–T : ST-segment –T wave URL : upper reference limit WHF : World Heart Federation WHO : World Health Organization Myocardial infarction (MI) can be recognised by clinical features, including electrocardiographic (ECG) findings, elevated values of biochemical markers (biomarkers) of myocardial necrosis, and by imaging, or may be defined by pathology. It is a major cause of death and disability worldwide. MI may be the first manifestation of coronary artery disease (CAD) or it may occur, repeatedly, in patients with established disease. Information on MI rates can provide useful information regarding the burden of CAD within and across populations, especially if standardized data are collected in a manner that …

Published
2012

13. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., Sirenko Y., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, and Sirenko, Y

Subjects
Endothelin receptor antagonist, Chronic thromboembolic pulmonary hypertension, Heart failure, Guideline, Prostacyclin analogue, Respiratory failure, Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension, Congenital heart disease, Connective tissue disease, Endothelin receptor antagonists, Guidelines, Heart failure, Left heart disease, Lung disease, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Pulmonary arterial hypertension, Pulmonary hypertension, Respiratory failure, Pulmonary hypertension, Phosphodiesterase type 5 inhibitor, Left heart disease, Lung disease, Connective tissue disease, Congenital heart disease
Abstract

Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanore (France), Riccardo Asteggiano (Italy), Luigi Paolo Badano (Italy), Joan Albert Barbera (Spain), Helene Bouvaist (France), Hector Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy), Graca Castro (Portugal), Cetin Erol (Turkey), Volkmar Falk (Germany), Christian Funck-Brentano (France), Matthias Gorenflo (Germany), John Granton (Canada), Bernard Iung (France), David G. Kiely (UK), Paulus Kirchhof (Germany/UK), Barbro Kjellstrom (Sweden), Ulf Landmesser (Switzerland), John Lekakis (Greece), Christos Lionis (Greece), Gregory Y. H. Lip (UK), Stylianos E. Orfanos (Greece), Myung H. Park (USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marie-Pierre Revel (France), David Rigau (ERS methodologist) (Switzerland), Stephan Rosenkranz (Germany), Heinz Voller (Germany), and Jose Luis Zamorano (Spain)

Published
2016

14. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

Author

Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Agladze V, Aliot E, Balabanski T, Blomstrom Lundqvist C, Capucci A, Crijns H, Dahlöf B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, PERRONE FILARDI, PASQUALE, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I, European Heart Rhythm Association, European Association for Cardio Thoracic Surgery, ESC Committee for Practice Guidelines, Document Reviewers, Camm, Aj, Kirchhof, P, Lip, Gy, Schotten, U, Savelieva, I, Ernst, S, Van Gelder, Ic, Al Attar, N, Hindricks, G, Prendergast, B, Heidbuchel, H, Alfieri, O, Angelini, A, Atar, D, Colonna, P, De Caterina, R, De Sutter, J, Goette, A, Gorenek, B, Heldal, M, Hohloser, Sh, Kolh, P, Le Heuzey, Jy, Ponikowski, P, Rutten, Fh, Vahanian, A, Auricchio, A, Bax, J, Ceconi, C, Dean, V, Filippatos, G, Funck Brentano, C, Hobbs, R, Kearney, P, Mcdonagh, T, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Vardas, Pe, Widimsky, P, Agladze, V, Aliot, E, Balabanski, T, Blomstrom Lundqvist, C, Capucci, A, Crijns, H, Dahlöf, B, Folliguet, T, Glikson, M, Goethals, M, Gulba, Dc, Ho, Sy, Klautz, Rj, Kose, S, Mcmurray, J, PERRONE FILARDI, Pasquale, Raatikainen, P, Salvador, Mj, Schalij, Mj, Shpektor, A, Sousa, J, Stepinska, J, Uuetoa, H, Zamorano, Jl, Zupan, I, European Heart Rhythm, Association, European Association for Cardio Thoracic, Surgery, ESC Committee for Practice, Guideline, Document, Reviewers, Alfieri, Ottavio, Ponikowski, P., Fysiologie, Cardiologie, RS: CARIM School for Cardiovascular Diseases, Camm, A. J, Lip, G, Van Gelder, I. C, Hohloser, S. H, and Le Heuzey, J. Y.

Subjects
Lung Diseases, Male, Rate control, Heart Valve Diseases, Management of atrial fibrillation, Angiotensin-Converting Enzyme Inhibitors, Comorbidity, Upstream therapy, Hyperthyroidism, law.invention, Cardiac Resynchronization Therapy, Electrocardiography, Ventricular Dysfunction, Left, Postoperative Complications, Atrial fibrillation European Society of Cardiology Guidelines Anticoagulation Rate control Rhythm control Upstream therapy Pulmonary vein isolation Left atrial ablation randomized controlled-trial congestive-heart-failure parkinson-white-syndrome cardiac resynchronization therapy angiotensin-converting enzyme polyunsaturated fatty-acids antiarrhythmic-drug therapy long-term survival radiofrequency catheter ablation placebo-controlled trial, Randomized controlled trial, Heart Rate, Pregnancy, Recurrence, law, Prevalence, Secondary Prevention, Medicine, Angioplasty, Balloon, Coronary, Precision Medicine, Mineralocorticoid Receptor Antagonists, Middle Aged, Congestive-Heart-Failure, Left atrial ablation, Primary Prevention, Stroke, Catheter Ablation, Cardiology, Female, Rhythm control, Cardiology and Cardiovascular Medicine, Risk assessment, Anti-Arrhythmia Agents, Sports, Radiofrequency Catheter Ablation, Adult, medicine.medical_specialty, Point-of-Care Systems, Angiotensin-Converting Enzyme, Antiarrhythmic-Drug Therapy, Placebo-Controlled Trial, Electric Countershock, MEDLINE, Hemorrhage, Guidelines, Parkinson-White-Syndrome, Risk Assessment, Pulmonary vein isolation, European Society of Cardiology, Anticoagulation, Fibrinolytic Agents, Thromboembolism, Internal medicine, Diabetes Mellitus, Humans, Polyunsaturated Fatty-Acids, International Normalized Ratio, Acute Coronary Syndrome, Randomized Controlled-Trial, Long-Term Survival, Aged, Heart Failure, Intraoperative Care, business.industry, Conflict of interest, Anticoagulants, Evidence-based medicine, Cardiomyopathy, Hypertrophic, Precision medicine, Atrial fibrillation, Athletes, CHA2DS2–VASc score, Quality of Life, Wolff-Parkinson-White Syndrome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Platelet Aggregation Inhibitors
Abstract

Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A large number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC Web Site (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales, as outlined in Tables 1 and 2 . View this table: Table 1 Classes of recommendations View this table: Table 2 Levels of evidence The experts of the writing panels have provided disclosure statements of all relationships they may have that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task Force report received its entire financial support from …

Published
2010

15. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Author

Camm, Aj, Lip, Gy, De Caterina, R, Savelieva, I, Atar, D, Hohnloser, Sh, Hindricks, G, Kirchhof, P, Bax, Jj, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Vardas, P, Al Attar, N, Alfieri, O, Angelini, Annalisa, Blömstrom Lundqvist, C, Colonna, P, De Sutter, J, Ernst, S, Goette, A, Gorenek, B, Hatala, R, Heidbüchel, H, Heldal, M, Kristensen, Sd, Le Heuzey JY, Mavrakis, H, Mont, L, Filardi, Pp, Ponikowski, P, Prendergast, B, Rutten, Fh, Schotten, U, Van Gelder IC, Verheugt, Fw, Authors/Task Force Members, ESC Committee for Practice Guidelines, Document, Reviewers, Authors/Task Force, Member, Camm, Aj, Lip, Gy, De Caterina, R, Savelieva, I, Atar, D, Hohnloser, Sh, Hindricks, G, Kirchhof, P, ESC Committee for Practice, Guideline, Bax, Jj, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewer, Vardas, P, Al Attar, N, Alfieri, Ottavio, Angelini, A, Bl√∂mstrom Lundqvist, C, Colonna, P, De Sutter, J, Ernst, S, Goette, A, Gorenek, B, Hatala, R, Heidb√ºchel, H, Heldal, M, Kristensen, Sd, Le Heuzey, Jy, Mavrakis, H, Mont, L, Filardi, Pp, Ponikowski, P, Prendergast, B, Rutten, Fh, Schotten, U, Van Gelder, Ic, and Verheugt, Fw

Subjects
Heart Failure, Electric Countershock, Anticoagulants, Hemorrhage, atrial fibrillation, guidelines, Risk Assessment, Stroke, Early Diagnosis, Thromboembolism, Atrial Fibrillation, Catheter Ablation, Humans, Atrial Appendage, Therapeutic Occlusion, Anti-Arrhythmia Agents
Published
2012

16. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Author

Steg, Pg, James, Sk, Atar, D, Badano, Lp, Lundqvist, Cb, Borger, Ma, Di Mario, C, Dickstein, K, Ducrocq, G, Fernandez Aviles, F, Gershlick, Ah, Giannuzzi, P, Halvorsen, S, Huber, K, Juni, P, Kastrati, A, Knuuti, J, Lenzen, Mj, Mahaffey, Kw, Valgimigli, M, Van't Hof, A, Widimsky, P, Zahger, D, ESC Committee for Practice Guidelines, Bax, Jj, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewers, Astin, F, Aström Olsson, K, Budaj, A, Clemmensen, P, Collet, Jp, Fox, Ka, Fuat, A, Gustiene, O, Hamm, Cw, Kala, P, Lancellotti, P, Maggioni, Ap, Merkely, B, Neumann, Fj, Piepoli, Mf, Van de Werf, F, Verheugt, F, Wallentin, L., Steg, P, James, S, Atar, D, Badano, L, Lundqvist, C, Borger, M, Di Mario, C, Dickstein, K, Ducrocq, G, Fernandez-Aviles, F, Gershlick, A, Giannuzzi, P, Halvorsen, S, Huber, K, Juni, P, Kastrati, A, Knuuti, J, Lenzen, M, Mahaffey, K, Valgimigli, M, Van'T Hof, A, Widimsky, P, Zahger, D, Bax, J, Baumgartner, H, Ceconi, C, Dean, V, Deaton, C, Fagard, R, Funck-Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Kolh, P, Mcdonagh, T, Moulin, C, Popescu, B, Reiner, Z, Sechtem, U, Sirnes, P, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Astin, F, Astrom-Olsson, K, Budaj, A, Clemmensen, P, Collet, J, Fox, K, Fuat, A, Gustiene, O, Hamm, C, Kala, P, Lancellotti, P, Maggioni, A, Merkely, B, Neumann, F, Piepoli, M, Van De Werf, F, Verheugt, F, and Wallentin, L

Subjects
Emergency Medical Services, Biomedical Research, General Practice, Myocardial Infarction, Guideline, Anxiety, ST-segment elevation, Electrocardiography, Myocardial infarction, Coronary Artery Bypass, 610 Medicine & health, Fibrinolytic Agent, Cardiovascular diseases [NCEBP 14], Secondary prevention, General Medicine, Reperfusion therapy, Antifibrinolytic Agents, Exercise Therapy, Hospitalization, cardiovascular system, Cardiology, Acute coronary syndromes Ischaemic heart disease, Cardiomyopathies, Cardiology and Cardiovascular Medicine, Ticagrelor, Human, medicine.drug, Acute coronary syndrome, medicine.medical_specialty, Cardiotonic Agents, Pain, Myocardial Reperfusion, Acute myocardial infarction, Guidelines, Antifibrinolytic Agent, Risk Assessment, Time-to-Treatment, Percutaneous Coronary Intervention, Fibrinolytic Agents, Internal medicine, medicine, Humans, Cardiotonic Agent, Hemodynamic, cardiovascular diseases, Emergency Treatment, Cardiomyopathie, Heart Failure, Cardiac Imaging Technique, Management of acute coronary syndrome, Emergency Medical Service, business.industry, Coronary Artery Bypa, Platelet Aggregation Inhibitor, Hemodynamics, Arrhythmias, Cardiac, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, Long-Term Care, Primary percutaneous coronary intervention Antithrombotic therapy, Cardiac Imaging Techniques, Dyspnea, Hyperglycemia, Door-to-balloon, Myocardial infarction complications, Myocardial infarction diagnosis, business, Risk Reduction Behavior, Platelet Aggregation Inhibitors, Out-of-Hospital Cardiac Arrest, Forecasting
Abstract

ACE : angiotensin-converting enzyme ACS : acute coronary syndrome ADP : adenosine diphosphate AF : atrial fibrillation AMI : acute myocardial infarction AV : atrioventricular AIDA-4 : Abciximab Intracoronary vs. intravenously Drug Application APACHE II : Acute Physiology Aand Chronic

Published
2012

17. ESC Guidelines on the management of cardiovascular diseases during pregnancy

Author

European Society of Gynecology, Association for European Paediatric Cardiology, German Society for Gender Medicine, Authors/Task Force Members, Regitz Zagrosek V., Blomstrom Lundqvist C., Cifkova R., Ferreira R., Foidart J. M., Gibbs J. S., Gohlke Baerwolf C., Gorenek B., Iung B., Kirby M., Maas A. H., Morais J., Nihoyannopoulos P., Pieper P. G., Presbitero P., Roos Hesselink J. W., Schaufelberger M., Seeland U., Torracca L, ESC Committee for Practice Guidelines, Bax J., Auricchio A., Baumgartner H., Ceconi C., Dean V., Deaton C., Fagard R., Funck Brentano C., Hasdai D., Hoes A., Knuuti J., Kolh P., McDonagh T., Moulin C., Poldermans D., Popescu B. A., Reiner Z., Sechtem U., Sirnes P. A., Torbicki A., Vahanian A., Windecker S., Document Reviewers, Aguiar C., Al Attar N., Garcia A. A., Antoniou A., Coman I., Elkayam U., Gomez Sanchez M. A., Gotcheva N., Hilfiker Kleiner D., Kiss R. G., Kitsiou A., Konings K. T., Lip G. Y., Manolis A., Mebaaza A., Mintale I., Morice M. C., Mulder B. J., Pasquet A., Price S., Priori S. G., Salvador M. J., Shotan A., Silversides C. K., Skouby S. O., Stein J. I., Tornos P., Vejlstrup N., Walker F., Warnes C., BORGHI, CLAUDIO, European Society of Gynecology, Association for European Paediatric Cardiology, German Society for Gender Medicine, Authors/Task Force Members, Regitz-Zagrosek V., Blomstrom Lundqvist C., Borghi C., Cifkova R., Ferreira R., Foidart J.M., Gibbs J.S., Gohlke-Baerwolf C., Gorenek B., Iung B., Kirby M., Maas A.H., Morais J., Nihoyannopoulos P., Pieper P.G., Presbitero P., Roos-Hesselink J.W., Schaufelberger M., Seeland U., Torracca L, ESC Committee for Practice Guidelines, Bax J., Auricchio A., Baumgartner H., Ceconi C., Dean V., Deaton C., Fagard R., Funck-Brentano C., Hasdai D., Hoes A., Knuuti J., Kolh P., McDonagh T., Moulin C., Poldermans D., Popescu B.A., Reiner Z., Sechtem U., Sirnes P.A., Torbicki A., Vahanian A., Windecker S., and Document Reviewers, Baumgartner H., Deaton C., Aguiar C., Al-Attar N., Garcia A.A., Antoniou A., Coman I., Elkayam U., Gomez-Sanchez M.A., Gotcheva N., Hilfiker-Kleiner D., Kiss R.G., Kitsiou A., Konings K.T., Lip G.Y., Manolis A., Mebaaza A., Mintale I., Morice M.C., Mulder B.J., Pasquet A., Price S., Priori S.G., Salvador M.J., Shotan A., Silversides C.K., Skouby S.O., Stein J.I., Tornos P., Vejlstrup N., Walker F., Warnes C.

Subjects
Counseling, Prenatal Diagnosi, Pregnancy Complications, Cardiovascular, Heart failure, Abortion, Induced, Prenatal Care, Venous Thromboembolism, Guideline, Cardiovascular disease, Aortic Disease, Valvular heart disease, Management, Congential heart disease, Heart Disease, Cardiovascular Agent, Pregnancy, Hypertension, Pregnancy Complications, Infectiou, Female, Cardiology and Cardiovascular Medicine, Arrhythmia, Risk assessment, Human
Abstract

not available

Published
2011

18. Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II)

Author

Bacquet, P, Levy, E, Mcguire, A, Mcmurray, J, Merot, Jl, Paschen, B, Remme, Wj, Szucs, Td, Klein, W, Brunhuber, W, Hofmann, R, Kuhn, P, Nesser, Hj, Slany, J, Weihs, W, Wiedermann, C, Wimmer, H, van Mieghem, W, Boland, J, Chaudron, Jm, Jordaens, L, Melchior, Jp, Aschermann, M, Bruthansl, J, Hradec, M, Kolbel, F, Semrad, B, Haghfelt, T, Hansen, Jf, Goetzsche, Co, Hildebrandt, P, Kassis, E, Rasmussen, V, Rokkedal, J, Thomassen, A, Groundstroem, K, Uusimaa, P, Le Heuzey JY, Aumont, Mc, Aupetit, Jf, Baille, N, Baudouy, P, Belin, A, Bonneau, A, Bonneric, G, Bousser, Jp, Citron, B, Dary, P, Decoulx, E, De Groote, P, Denolle, T, Dievart, F, Duriez, P, Eicher, Jc, Enjuto, G, Ferriere, M, Fournier, E, Garandeau, M, Gauthier, J, Genest, M, Gerbe, A, Godenir, Jp, Guillot, B, Guillot, Jp, Guillot, P, Heno, P, D'Ivernois, C, Jean, M, Kacet, S, Kalle, R, Komajda, M, Lacroix, A, Lallemand, R, Lardoux, H, Marquet, M, Martin, M, Martin, O, Mery, D, Mossaz, R, Mothes, P, Olive, T, Ostorero, M, Paganelli, F, Page, E, Pauly Laubry, C, Puel, J, Rousseau, Jf, Roux, Jj, Schenowitz, A, Sourdais, K, Tremel, F, Verdun, A, Witchiz, S, Wolf, Je, Hombach, V, Assmann, I, Beyer, T, Bischoff, Ko, Darius, H, Ertl, G, Fleck, E, Forster, K, Freytag, F, Gleichmann, U, Haasis, R, Henssge, R, Hey, D, Hesse, P, Hofs, T, Keck, M, Klein, H, Kromer, Et, Kruls Munch, J, Luderitz, B, Maisch, B, Mitrovic, V, Neubauer, S, Osterziel, Kj, Simon, H, Spitzer, Sg, Stohring, R, Taubert, G, Teichmann, W, Theisen, K, Wende, W, Wieser, H, Zotz, R, Bridges, A, Adgey, J, Ambepitiya, G, Boon, N, Boyle, Rm, Cowley, Aj, Cripps, T, Davies, Mk, Dunn, F, Findlay, J, Forsey, P, Fyfe, T, Gould, B, Greenwood, Tw, Hubner, P, Khan, S, Lewis, P, Mackay, A, Maltz, M, Mcarthur, J, Mcleod, A, Mcleod, D, Metcalfe, M, Millar Craig, M, Mills, P, Nelson, Jk, Nicholls, D, Oakley, Gd, Patterson, Dlh, Pohl, Jef, Ray, S, Silke, B, Wilkinson, Pr, Preda, I, Csanady, M, Cserhalmi, L, Edes, I, Gesztesi, T, Karpati, P, Simon, K, Tarjan, J, Fogari, R, Tramarin, R, Galie, N, Giani, P, Milanese, U, Scalvini, S, Scrutinio, D, Sechi, Leonardo Alberto, Tettamanti, F, De Vito, F, Crean, P, Mccann, H, Mulcahy, D, Sugrue, D, van Hoogenhuyze DCA, van der Burgh PH, Ciampricotti, R, van Dantzig JM, Denhartog, Fr, Henneman, Ja, van Kesteren HAM, Kragten, Ja, Liem, Kl, Limburg, A, van der Linde MR, Linssen, Gcm, Pasteuning, H, Penn, Hjam, Van Rossum, P, Schaafsma, Hj, Schelling, A, Sloos, R, Wesdorp, Jcl, Korewicki, J, Achremczyk, P, Czestockowska, E, Dowgird, M, Dyduszynski, A, Gorski, J, Ilmurzynska, K, Janicki, K, Kornacewicz Jach, Z, Kraska, T, Krzeminska Pakula, M, Kuch, J, Nartowicz, E, Petelenz, T, Piwowarska, W, Rawczynska Englert, I, Ruzyllo, W, Swiatecka, G, Tendera, M, Wierzchowiecki, M, Wodniecki, J, Wojciechowoski, D, Wrabec, K, Wysocki, H, Gomes, Rs, Ceia, Mf, Lousada, N, Campos, Jmm, Providencia, La, de Moura ALZC, Marejev, Vj, Aronov, Dm, Arutjunov, Gp, Bart, Bj, Basechikin, Ss, Belenkov, Jn, Beloussov, Jb, Bokeria, Oa, Charchogljan, Ra, Doschytsin, V, Fedorova, Ta, Glezer, Mg, Gorbachenkov, A, Gorshkov, Gospodarenko, Al, Ivashkin, Vt, Ivleva, Aj, Kyrichenko, Aa, Lavrov, Aa, Lazebnik, Lb, Marynov, A, Mazaev, Vp, Polejev, Nr, Shpektor, Sidorenko, Ba, Sobolev, Ke, Starodoubtsev, Ak, Storozhakhov, Gi, Syrkin, Al, Zodionchenko, Vs, Zvereva, Tv, Murin, J, Kaliska, G, Rybar, R, Valle, V, Artaza, M, Conthe, P, Cruz, Jm, Garcia Moll, M, Lopez Sendon JL, Martinez, A, Monzon, F, Ribas, M, Roig, E, Roldan, I, Hoglund, C, Ekdahl, S, Hjelmaeus, L, Lindberg, K, Lofdahl, P, Ulvenstam, G, Warselius, L, Follath, F, Anghern, W, Dubach, P, Erne, P, Gallino, A, Moccetti, T, Jmouro, Av, Dargie, Hj, Erdmann, E, Lechat, P, Sendon, Jll, Mareyev, V, Sadowski, Z, Seabra Gomes RJ, Zannad, F, Wehrlen Grandjean, M, Funck Brentano, C, Hansen, S, Hohnloser, S, Vanoli, E, Jaillon, P, De Baker, G, Dahlstrom, U, Hill, C, Leizorovicz, A, Burgnard, F, Rolland, C, Wiemann, H, Verkenne, P, Arab, T, Cussac, N, Dussous, V, Haise, S, and Funck Brentano, C.

Subjects
H Social Sciences (General), medicine.medical_specialty, Cost-Benefit Analysis, Adrenergic beta-Antagonists, METOPROLOL, Placebo, THERAPY, Indirect costs, Pharmacoeconomics, Pharmacotherapy, RANDOMIZED INTERVENTION TRIAL, PHARMACOECONOMICS, Germany, Health care, Bisoprolol, Humans, Medicine, Outpatient clinic, Prospective Studies, Intensive care medicine, health care economics and organizations, Heart Failure, CARVEDILOL, business.industry, MORTALITY, Diagnosis-related group, United Kingdom, Chemotherapy, Adjuvant, MERIT-HF, HOSPITALIZATION, MINIMIZATION, INHIBITORS, France, Quality-Adjusted Life Years, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract

Background Beta-blockers, used as an adjunctive to diuretics, digoxin and angiotensin converting enzyme inhibitors, improve survival in chronic heart failure. We report a prospectively planned economic analysis of the cost of adjunctive beta-blocker therapy in the second Cardiac Insufficiency BIsoprolol Study (CIBIS II). Methods Resource utilization data (drug therapy, number of hospital admissions, length of hospital stay, ward type) were collected prospectively in all patients in CIBIS . These data were used to determine the additional direct costs incurred, and savings made, with bisoprolol therapy. As well as the cost of the drug, additional costs related to bisoprolol therapy were added to cover the supervision of treatment initiation and titration (four outpatient clinic/office visits). Per them (hospital bed day) costings were carried out for France, Germany and the U.K. Diagnosis related group costings were performed for France and the U.K. Our analyses took the perspective of a third party payer in France and Germany and the National Health Service in the U.K. Results Overall, fewer patients were hospitalized in the bisoprolol group, there were fewer hospital admissions perpatient hospitalized, fewer hospital admissions overall, fewer days spent in hospital and fewer days spent in the most expensive type of ward. As a consequence the cost of care in the bisoprolol group was 5-10% less in all three countries, in the per them analysis, even taking into account the cost of bisoprolol and the extra initiation/up-titration visits. The cost per patient treated in the placebo and bisoprolol groups was FF35 009 vs FF31 762 in France, DM11 563 vs DM10 784 in Germany and pound 4987 vs pound 4722 in the U.K. The diagnosis related group analysis gave similar results. Interpretation Not only did bisoprolol increase survival and reduce hospital admissions in CIBIS II, it also cut the cost of care in so doing. This `win-win' situation of positive health benefits associated with cost savings is Favourable from the point of view of both the patient and health care systems. These findings add further support for the use of beta-blockers in chronic heart failure.

Published
2001

19. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

Author

Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., Deaton, C., Ebrahim, S., Fisher, M., Germano, G., Hobbs, R., Hoes, A., Karadeniz, S., Mezzani, A., Prescott, E., Ryden, L., Scherer, M., Syvanne, M., Scholte Op Reimer, W. J. M., Vrints, C., Wood, D., Zamorano, J. L., Zannad, F., Cooney, M. T., Bax, J., Baumgartner, H., Ceconi, C., Dean, V., Fagard, R., Funck Brentano, C., Hasdai, D., Kirchhof, P., Knuuti, J., Kolh, P., Mcdonagh, T., Moulin, C., Popescu, B. A., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S., Aboyans, V., Ezquerra, E. A., Baigent, C., Brotons, C., Burell, G., Ceriello, A., De Sutter, J., Deckers, J., Del Prato, S., Diener, H. C., Fitzsimons, D., Fras, Z., Hambrecht, R., Jankowski, P., Keil, U., Kirby, M., Larsen, M. L., Mancia, G., Manolis, A. J., Mcmurray, J., Pajak, A., Parkhomenko, A., Rallidis, L., Rigo, F., Rocha, E., Ruilope, L. M., Van Der Velde, E., Vanuzzo, D., Viigimaa, M., Volpe, Massimo, Wiklund, O., Wolpert, C., Authors/task Force Members, Parts Of The Guidelines:, Other Experts Who Contributed T. O., Esc, Committee For Practice Guidelines :., Document, Reviewers, School of Health and Caring Sciences, Linnaeus University, Department of Public Health, University of Gent, University Hospital Center Zagreb, 2nd Department of Internal Medicine, Faculty of Epidemiology and Population Health [London], London School of Hygiene and Tropical Medicine (LSHTM), Primary Care Clinical Sciences, University of Birmingham [Birmingham], Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), and Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Epidemiology, medicine.medical_treatment, General Practice, physical activity, Blood Pressure, Smoking Prevention, Comorbidity, prevention, Electronic Health Records, Myocardial infarction, ComputingMilieux_MISCELLANEOUS, education.field_of_study, Rehabilitation, Cardiac Rehabilitation, Evidence-Based Medicine, Prognosis, Cardiovascular disease, Lipids, Drug Combinations, nutrition, Cardiovascular Diseases, Cardiology and Cardiovascular Medicine, Diagnostic Imaging, medicine.medical_specialty, Hypercholesterolemia, Advisory Committees, Health Promotion, Risk Assessment, Medication Adherence, European guidelines, cardiovascular disease prevention, Humans, education, Physician's Role, Exercise, Life Style, Aged, Primary Health Care, Patient Selection, Cardiovascular Agents, medicine.disease, Self Care, Health promotion, Early Diagnosis, Diabetes Mellitus, Type 2, Cardiology, Disease prevention, Risk Reduction Behavior, Biomarkers, Diabetic Angiopathies, Systolic hypertension, Risk Factors, Preventive Health Services, Applied Psychology, Middle Aged, Clopidogrel, Clinical Practice, Hospitalization, Europe, Treatment Outcome, Heart Function Tests, Hypertension, Female, Heart Protection Study, medicine.drug, Adult, Consensus, United Kingdom Prospective Diabetes Study, Population, MEDLINE, psychosocial factors, risk assessment, risk management, smoking, Nurse's Role, Predictive Value of Tests, Internal medicine, medicine, Obesity, cardiovascular diseases, Antihypertensive Agents, Task force, business.industry, Percutaneous coronary intervention, Diet, Socioeconomic Factors, Family medicine, Heart failure, Chronic Disease, Smoking Cessation, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Delivery of Health Care, Stress, Psychological, Kidney disease
Abstract

ABI : ankle–brachial index ACCORD : Action to Control Cardiovascular Risk in Diabetes ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation AGREE : Appraisal of Guidelines Research and Evaluation AHA : American Heart Association apoA1 : apolipoprotein A1 apoB : apolipoprotein B CABG : coronary artery bypass graft surgery CARDS : Collaborative AtoRvastatin Diabetes Study CCNAP : Council on Cardiovascular Nursing and Allied Professions CHARISMA : Clopidogrel for High Athero-thrombotic Risk and Ischemic Stabilisation, Management, and Avoidance CHD : coronary heart disease CKD : chronic kidney disease COMMIT : Clopidogrel and Metoprolol in Myocardial Infarction Trial CRP : C-reactive protein CURE : Clopidogrel in Unstable Angina to Prevent Recurrent Events CVD : cardiovascular disease DALYs : disability-adjusted life years DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Trial ED : erectile dysfunction eGFR : estimated glomerular filtration rate EHN : European Heart Network EPIC : European Prospective Investigation into Cancer and Nutrition EUROASPIRE : European Action on Secondary and Primary Prevention through Intervention to Reduce Events GFR : glomerular filtration rate GOSPEL : Global Secondary Prevention Strategies to Limit Event Recurrence After MI GRADE : Grading of Recommendations Assessment, Development and Evaluation HbA1c : glycated haemoglobin HDL : high-density lipoprotein HF-ACTION : Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing HOT : Hypertension Optimal Treatment Study HPS : Heart Protection Study HR : hazard ratio hsCRP : high-sensitivity C-reactive protein HYVET : Hypertension in the Very Elderly Trial ICD : International Classification of Diseases IMT : intima-media thickness INVEST : International Verapamil SR/Trandolapril JTF : Joint Task Force LDL : low-density lipoprotein Lp(a) : lipoprotein(a) LpPLA2 : lipoprotein-associated phospholipase 2 LVH : left ventricular hypertrophy MATCH : Management of Atherothrombosis with Clopidogrel in High-risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke MDRD : Modification of Diet in Renal Disease MET : metabolic equivalent MONICA : Multinational MONItoring of trends and determinants in CArdiovascular disease NICE : National Institute of Health and Clinical Excellence NRT : nicotine replacement therapy NSTEMI : non-ST elevation myocardial infarction ONTARGET : Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial OSA : obstructive sleep apnoea PAD : peripheral artery disease PCI : percutaneous coronary intervention PROactive : Prospective Pioglitazone Clinical Trial in Macrovascular Events PWV : pulse wave velocity QOF : Quality and Outcomes Framework RCT : randomized clinical trial RR : relative risk SBP : systolic blood pressure SCORE : Systematic Coronary Risk Evaluation Project SEARCH : Study of the Effectiveness of Additional Reductions in Cholesterol and SHEP : Systolic Hypertension in the Elderly Program STEMI : ST-elevation myocardial infarction SU.FOL.OM3 : SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids Syst-Eur : Systolic Hypertension in Europe TNT : Treating to New Targets UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use VITATOPS : VITAmins TO Prevent Stroke VLDL : very low-density lipoprotein WHO : World Health Organization ### 1.1 Introduction Atherosclerotic cardiovascular disease (CVD) is a chronic disorder developing insidiously throughout life and usually progressing to an advanced stage by the time symptoms occur. It remains the major cause of premature death in Europe, even though CVD mortality has …

Published
2012

20. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

Author

Mcmurray, Jj, Adamopoulos, S, Anker, Sd, Auricchio, A, Böhm, M, Dickstein, K, Falk, V, Filippatos, G, Fonseca, C, Gomez Sanchez MA, Jaarsma, T, Køber, L, Lip, Gy, Maggioni, Ap, Parkhomenko, A, Pieske, Bm, Popescu, Ba, Rønnevik, Pk, Rutten, Fh, Schwitter, J, Seferovic, P, Stepinska, J, Trindade, Pt, Voors, Aa, Zannad, F, Zeiher, A, Task Force for the Diagnosis, Treatment of Acute, Chronic Heart Failure 2012 of the European Society of Cardiology, Bax, Jj, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Kirchhof, P, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Torbicki, A, Vahanian, A, Windecker, S, Bonet, La, Avraamides, P, Ben Lamin HA, Brignole, M, Coca, A, Cowburn, P, Dargie, H, Elliott, P, Flachskampf, Fa, Guida, Gf, Hardman, S, Iung, B, Merkely, B, Mueller, C, Nanas, Jn, Nielsen, Ow, Orn, S, Parissis, Jt, Ponikowski, P, and ESC Committee for Practice Guidelines

Subjects
Beta-blockers, Ejection fraction, Transplantation, Digitalis, Heart failure, Natriuretic peptides, Reninangiotensin system, NO
Published
2012

21. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

Author

Regitz Zagrosek, V, Blomstrom Lundqvist, C, Borghi, C, Cifkova, R, Ferreira, R, Foidart, Jm, Gibbs, Js, Gohlke Baerwolf, C, Gorenek, B, Iung, B, Kirby, M, Maas, Ah, Morais, J, Nihoyannopoulos, P, Pieper, Pg, Presbitero, P, Roos Hesselink JW, Schaufelberger, M, Seeland, U, Torracca, L, ESC Committee for Practice Guidelines, Bax, J, Auricchio, A, Baumgartner, H, Ceconi, Claudio, Dean, V, Deaton, C, Fagard, R, Funck Brentano, C, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Mcdonagh, T, Moulin, C, Poldermans, D, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Torbicki, A, Vahanian, A, Windecker, S, Document, Reviewers, Aguiar, C, Al Attar, N, Garcia, Aa, Antoniou, A, Coman, I, Elkayam, U, Gomez Sanchez MA, Gotcheva, N, Hilfiker Kleiner, D, Kiss, Rg, Kitsiou, A, Konings, Kt, Lip, Gy, Manolis, A, Mebaaza, A, Mintale, I, Morice, Mc, Mulder, Bj, Pasquet, A, Price, S, Priori, Sg, Salvador, Mj, Shotan, A, Silversides, Ck, Skouby, So, Stein, Ji, Tornos, P, Vejlstrup, N, Walker, F, Warnes, C., ACS - Amsterdam Cardiovascular Sciences, and Cardiology

Subjects
Counseling, medicine.medical_specialty, Peripartum cardiomyopathy, Heart disease, Heart Diseases, Pregnancy Complications, Cardiovascular, Aortic Diseases, Coronary artery disease, Pregnancy, Internal medicine, Prenatal Diagnosis, Medicine, Humans, cardiovascular diseases, Pregnancy Complications, Infectious, Framingham Risk Score, business.industry, Contraindications, valvular heart disease, Atrial fibrillation, Abortion, Induced, Cardiovascular Agents, Prenatal Care, Venous Thromboembolism, medicine.disease, Heart failure, Cardiovascular agent, Hypertension, Cardiology, Female, Cardiology and Cardiovascular Medicine, business
Abstract

Table 1. Classes of recommendation Table 2. Levels of evidence Table 3. Estimated fetal and maternal effective doses for various diagnostic and interventional radiology procedures Table 4. Predictors of maternal cardiovascular events and risk score from the CARPREG study Table 5. Predictors of maternal cardiovascular events identified in congential heart diseases in the ZAHARA and Khairy study Table 6. Modified WHO classification of maternal cardiovascular risk: principles Table 7. Modified WHO classification of maternal cardiovascular risk: application Table 8. Maternal predictors of neonatal events in women with heart disease Table 9. General recommendations Table 10. Recommendations for the management of congenital heart disease Table 11. Recommendations for the management of aortic disease Table 12. Recommendations for the management of valvular heart disease Table 13. Recommendations for the management of coronary artery disease Table 14. Recommendations for the management of cardiomyopathies and heart failure Table 15. Recommendations for the management of arrhythmias Table 16. Recommendations for the management of hypertension Table 17. Check list for risk factors for venous thrombo-embolism Table 18. Prevalence of congenital thrombophilia and the associated risk of venous thrombo-embolism during pregnancy Table 19. Risk groups according to risk factors: definition and preventive measures Table 20. Recommendations for the prevention and management of venous thrombo-embolism in pregnancy and puerperium Table 21. Recommendations for drug use ABPM : ambulatory blood pressure monitoring ACC : American College of Cardiology ACE : angiotensin-converting enzyme ACS : acute coronary syndrome AF : atrial fibrillation AHA : American Heart Association aPTT : activated partial thromboplastin time ARB : angiotensin receptor blocker AS : aortic stenosis ASD : atrial septal defect AV : atrioventricular AVSD : atrioventricular septal defect BMI : body mass index BNP : B-type natriuretic peptide BP : blood pressure CDC : Centers for Disease Control CHADS : congestive heart failure, hypertension, age (>75 years), diabetes, stroke CI : confidence interval CO : cardiac output CoA : coarction of the aorta CT : computed tomography CVD : cardiovascular disease DBP : diastolic blood pressure DCM : dilated cardiomyopathy DVT : deep venous thrombosis ECG : electrocardiogram EF : ejection fraction ESC : European Society of Cardiology ESH : European Society of Hypertension ESICM : European Society of Intensive Care Medicine FDA : Food and Drug Administration HCM : hypertrophic cardiomyopathy ICD : implantable cardioverter-defibrillator INR : international normalized ratio i.v. : intravenous LMWH : low molecular weight heparin LV : left ventricular LVEF : left ventricular ejection fraction LVOTO : left ventricular outflow tract obstruction MRI : magnetic resonance imaging MS : mitral stenosis NT-proBNP : N-terminal pro B-type natriuretic peptide NYHA : New York Heart Association OAC : oral anticoagulant PAH : pulmonary arterial hypertension PAP : pulmonary artery pressure PCI : percutaneous coronary intervention PPCM : peripartum cardiomyopathy PS : pulmonary valve stenosis RV : right ventricular SBP : systolic blood pressure SVT : supraventricular tachycardia TGA : complete transposition of the great arteries TR : tricuspid regurgitation UFH : unfractionated heparin VSD : ventricular septal defect VT : ventricular tachycardia VTE : venous thrombo-embolism WHO : World Health Organization Guidelines summarize and evaluate all available evidence, at the time of the writing process, on a particular issue with the aim of assisting physicians in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes but are complements for textbooks and cover the European Society of Cardiology (ESC) Core Curriculum topics. Guidelines and recommendations should help the …

Published
2011

22. Effects of HIV Protease Inhibitors on Cardiac Conduction Velocity in Unselected HIV-Infected Patients.

Author

Charbit, B., Gayat, E., Voiriot, P., Boccara, F., Girard, P.-M., and Funck-Brentano, C.

Subjects
ANTIVIRAL agents, HIV infections, THERAPEUTICS, HIV-positive persons, HIGHLY active antiretroviral therapy, HIV protease inhibitors, ATRIOVENTRICULAR node, CORONARY disease, HEART failure
Abstract

We examined the prevalence and the extent of prolongation of the PR and QRS intervals and their relation to anti-HIV treatments and other clinical characteristics in 970 HIV-infected patients, 749 treated with antiretroviral therapy and 221 untreated. Age, body mass index, heart rate, and treatment with β-blockers and HIV protease inhibitors (PIs) were independent predictors of increase in the duration of the PR interval. Male gender, Caucasian ethnicity, heart rate, duration of antiretroviral therapy, and use of PIs were independent predictors of an increase in the duration of the QRS interval. Users of HIV PIs had an adjusted QRS-interval duration that was 2.6 ms (95% confidence interval (CI) 1.4-3.9) longer than the interval in nonusers (P = 0.0004). The adjusted odds ratios of first-degree atrioventricular block (n = 54) and complete bundle branch block (n = 23) were 1.62 (95% CI 0.90-2.89; P = 0.10) and 2.71 (95% CI 1.10-7.13; P = 0.03), respectively, in patients taking PIs. These findings may have important clinical implications, particularly with respect to QRS prolongation in patients with myocardial ischemia or heart failure. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

23. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

Giuseppe, Mancia, Robert, Fagard, Krzysztof, Narkiewicz, Josep, Redon, Alberto, Zanchetti, Michael, Böhm, Thierry, Christiaens, Renata, Cifkova, Guy, De Backer, Anna, Dominiczak, Maurizio, Galderisi, Diederick E, Grobbee, Tiny, Jaarsma, Paulus, Kirchhof, Sverre E, Kjeldsen, Stéphane, Laurent, Athanasios J, Manolis, Peter M, Nilsson, Luis Miguel, Ruilope, Roland E, Schmieder, Per Anton, Sirnes, Peter, Sleight, Margus, Viigimaa, Bernard, Waeber, Faiez, Zannad, Michel, Burnier, Ettore, Ambrosioni, Mark, Caufield, Antonio, Coca, Michael Hecht, Olsen, Costas, Tsioufis, Philippe, van de Borne, Jose Luis, Zamorano, Stephan, Achenbach, Helmut, Baumgartner, Jeroen J, Bax, Héctor, Bueno, Veronica, Dean, Christi, Deaton, Cetin, Erol, Roberto, Ferrari, David, Hasdai, Arno W, Hoes, Juhani, Knuuti, Philippe, Kolh, Patrizio, Lancellotti, Ales, Linhart, Petros, Nihoyannopoulos, Massimo F, Piepoli, Piotr, Ponikowski, Juan Luis, Tamargo, Michal, Tendera, Adam, Torbicki, William, Wijns, Stephan, Windecker, Denis L, Clement, Thierry C, Gillebert, Enrico Agabiti, Rosei, Stefan D, Anker, Johann, Bauersachs, Jana Brguljan, Hitij, Mark, Caulfield, Marc, De Buyzere, Sabina, De Geest, Geneviève Anne, Derumeaux, Serap, Erdine, Csaba, Farsang, Christian, Funck-Brentano, Vjekoslav, Gerc, Giuseppe, Germano, Stephan, Gielen, Herman, Haller, Jens, Jordan, Thomas, Kahan, Michel, Komajda, Dragan, Lovic, Heiko, Mahrholdt, Jan, Ostergren, Gianfranco, Parati, Joep, Perk, Jorge, Polonia, Bogdan A, Popescu, Zeljko, Reiner, Lars, Rydén, Yuriy, Sirenko, Alice, Stanton, Harry, Struijker-Boudier, Charalambos, Vlachopoulos, Massimo, Volpe, David A, Wood, Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, Mancia, Giuseppe, Fagard, Robert, Narkiewicz, Krzysztof, Redon, Josep, Zanchetti, Alberto, Böhm, Michael, Christiaens, Thierry, Cifkova, Renata, De Backer, Guy, Dominiczak, Anna, Galderisi, Maurizio, Grobbee, Diederick E., Jaarsma, Tiny, Kirchhof, Paulu, Kjeldsen, Sverre E., Laurent, Stéphane, Manolis, Athanasios J., Nilsson, Peter M., Ruilope, Luis Miguel, Schmieder, Roland E., Sirnes, Per Anton, Sleight, Peter, Viigimaa, Margu, Waeber, Bernard, Zannad, Faiez, Burnier, Michel, Ambrosioni, Ettore, Caufield, Mark, Coca, Antonio, Olsen, Michael Hecht, Tsioufis, Costa, Van De Borne, Philippe, Zamorano, Jose Lui, Achenbach, Stephan, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Dean, Veronica, Deaton, Christi, Erol, Cetin, Ferrari, Roberto, Hasdai, David, Hoes, Arno W., Knuuti, Juhani, Kolh, Philippe, Lancellotti, Patrizio, Linhart, Ale, Nihoyannopoulos, Petro, Piepoli, Massimo F., Ponikowski, Piotr, Tamargo, Juan Lui, Tendera, Michal, Torbicki, Adam, Wijns, William, Windecker, Stephan, Clement, Denis L., Gillebert, Thierry C., Rosei, Enrico Agabiti, Anker, Stefan D., Bauersachs, Johann, Hitij, Jana Brguljan, Caulfield, Mark, De Buyzere, Marc, De Geest, Sabina, Derumeaux, Geneviève Anne, Erdine, Serap, Farsang, Csaba, Funck Brentano, Christian, Gerc, Vjekoslav, Germano, Giuseppe, Gielen, Stephan, Haller, Herman, Jordan, Jen, Kahan, Thoma, Komajda, Michel, Lovic, Dragan, Mahrholdt, Heiko, Ostergren, Jan, Parati, Gianfranco, Perk, Joep, Polonia, Jorge, Popescu, Bogdan A., Reiner, Željko, Rydén, Lar, Sirenko, Yuriy, Stanton, Alice, Struijker Boudier, Harry, Vlachopoulos, Charalambo, Volpe, Massimo, and Wood, David A.

Subjects
Male, Systolic hypertension, Medical Informatic, Blood Pressure, Guideline, Retinal Disease, chemistry.chemical_compound, Electrocardiography, Pregnancy, Risk Factors, Antihypertensive treatment, Cardiovascular Disease, Diabetes Complication, Drug Interactions, Metabolic Syndrome, Brain Diseases, Sleep Apnea, Obstructive, Follow-up, Metabolic Syndrome X, Brain Disease, Organ damage, Blood Pressure Monitoring, Ambulatory, Middle Aged, Device therapy, Antihypertensive Agent, Heart Disease, Drug Interaction, Cardiovascular Diseases, Echocardiography, Cerebrovascular Disorder, Hypertension, Cardiology, Drug Therapy, Combination, Female, Cardiology and Cardiovascular Medicine, Human, medicine.drug, Adult, medicine.medical_specialty, Ambulatory blood pressure, Heart Diseases, Hormone Replacement Therapy, 610 Medicine & health, Risk Assessment, Perioperative Care, Diabetes Complications, Young Adult, Retinal Diseases, Internal medicine, Weight Loss, medicine, Humans, Blood pressure measurement, Renal Insufficiency, Chronic, Exercise, Physical Examination, Perindopril/indapamide, Antihypertensive Agents, Aged, Patient Care Team, business.industry, Platelet Aggregation Inhibitor, Risk Factor, Cardiovascular complication, Hypertension, Pregnancy-Induced, Aliskiren, Cardiovascular risk, Lifestyle, medicine.disease, Weight Lo, Diet, Candesartan, Cerebrovascular Disorders, Sexual Dysfunction, Physiological, Blood pressure, chemistry, Heart failure, Hyperglycemia, Smoking Cessation, Telmisartan, business, Delivery of Health Care, Risk Reduction Behavior, Medical Informatics, Platelet Aggregation Inhibitors, Contraceptives, Oral
Abstract

ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

Published
2013

24. Guidelines on myocardial revascularization

Author

Task Force on Myocardial Revascularization of the European Society of Cardiology, the European Association for Cardio Thoracic Surgery, European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Collaborators: Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck Bretano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Dunning J, Elia S, Kappetein P, Lockowandt U, Sarris G, Vouohe P, von Segesser L, Agewall S, Aladashvili A, Alexopoulos D, Antunes MJ, Atalar E, de la Riviere AB, Doganov A, Eha J, Fajadet J, Ferreira R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Laufer G, Legrand V, Nashef SA, Neumann FJ, Niemela K, Nihoyannopoulos P, Noc M, Piek JJ, Pirk J, Rozenman Y, Sabate M, Starc R, Thielmann M, Wheatley DJ, Windecker S, Zembala M., ALFIERI , OTTAVIO, ACS - Amsterdam Cardiovascular Sciences, Cardiology, Task Force on Myocardial Revascularization of the European Society of, Cardiology, the European Association for Cardio Thoracic, Surgery, European Association for Percutaneous Cardiovascular, Intervention, Kolh, P, Wijns, W, Danchin, N, Di Mario, C, Falk, V, Folliguet, T, Garg, S, Huber, K, James, S, Knuuti, J, Lopez Sendon, J, Marco, J, Menicanti, L, Ostojic, M, Piepoli, Mf, Pirlet, C, Pomar, Jl, Reifart, N, Ribichini, Fl, Schalij, Mj, Sergeant, P, Serruys, Pw, Silber, S, Sousa Uva, M, Taggart D., Collaborators: Vahanian A, Auricchio, A, Bax, J, Ceconi, C, Dean, V, Filippatos, G, Funck Brentano, C, Hobbs, R, Kearney, P, Mcdonagh, T, Popescu, Ba, Reiner, Z, Sechtem, U, Sirnes, Pa, Tendera, M, Vardas, Pe, Widimsky, P, Alfieri, Ottavio, Dunning, J, Elia, S, Kappetein, P, Lockowandt, U, Sarris, G, Vouhe, P, von Segesser, L, Agewall, S, Aladashvili, A, Alexopoulos, D, Antunes, Mj, Atalar, E, de la Riviere, Ab, Doganov, A, Eha, J, Fajadet, J, Ferreira, R, Garot, J, Halcox, J, Hasin, Y, Janssens, S, Kervinen, K, Laufer, G, Legrand, V, Nashef, Sa, Neumann, Fj, Niemela, K, Nihoyannopoulos, P, Noc, M, Piek, Jj, Pirk, J, Rozenman, Y, Sabate, M, Starc, R, Thielmann, M, Wheatley, Dj, Windecker, S, Zembala, M., Funck Bretano, C, and Vouohe, P

Subjects
Carotid Artery Diseases, Graft Rejection, lcsh:Diseases of the circulatory (Cardiovascular) system, Judgement, Settore MED/21 - Chirurgia Toracica, Medizin, Heart Valve Diseases, Myocardial Ischemia, Contrast Media, Myocardial Revascularization, Assisted Circulation, General Environmental Science, Drug-Eluting Stents, General Medicine, Prognosis, Europe, Stroke, Acute Disease, Cardiology, Platelet aggregation inhibitor, Kidney Diseases, Medical emergency, Cardiology and Cardiovascular Medicine, Risk assessment, Pulmonary and Respiratory Medicine, Diagnostic Imaging, medicine.medical_specialty, Myocardial revascularization, MEDLINE, Renal Artery Obstruction, Risk Assessment, End stage renal disease, Blood Vessel Prosthesis Implantation, Fibrinolytic Agents, Patient Education as Topic, Internal medicine, Preoperative Care, medicine, Humans, Hypoglycemic Agents, Heart Failure, Postoperative Care, business.industry, Contraindications, Conflict of interest, Arrhythmias, Cardiac, Evidence-based medicine, medicine.disease, lcsh:RC666-701, Chronic Disease, General Earth and Planetary Sciences, Surgery, business, Fibrinolytic agent, Diabetic Angiopathies, Platelet Aggregation Inhibitors
Abstract

Guidelines and Expert Consensus Documents summarize and evaluate all available evidence with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome and the risk benefit ratio of diagnostic or therapeutic means. Guidelines are no substitutes for textbooks and their legal implications have been discussed previously. Guidelines and recommendations should help physicians to make decisions in their daily practice. However, the ultimate judgement regarding the care of an individual patient must be made by his/her responsible physician(s). The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (http://www.escardio.org/knowledge/ guidelines/rules). Members of this Task Force were selected by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) to represent all physicians involved with the medical and surgical care of patients with coronary artery disease (CAD). A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk benefit ratio. Estimates of expected health outcomes for society are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in Tables 1 and 2. The members of the Task Force have provided disclosure statements of all relationships that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at European Heart House, headquarters of the ESC. Any changes in conflict of interest that arose during the writing period were notified to the ESC. The Task Force report received its entire financial support from the ESC and EACTS, without any involvement of the pharmaceutical, device, or surgical industry. ESC and EACTS Committees for Practice Guidelines are responsible for the endorsement process of these joint Guidelines. The finalized document has been approved by all the experts involved in the Task Force, and was submitted to outside specialists selected by both societies for review. The document is revised, and finally approved by ESC and EACTS and subsequently published simultaneously in the European Heart Journal and the European Journal of Cardio-Thoracic Surgery. After publication, dissemination of the Guidelines is of paramount importance. Pocket-sized versions and personal digital assistant-downloadable versions are useful at the point of care. Some surveys have shown that the intended users are sometimes unaware of the existence of guidelines, or simply do not translate them into practice. Thus, implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results